Endometriosis Patients Undergoing Quinagolide Treatment

This study has been completed.
Sponsor:
Information provided by:
Instituto Valenciano de Infertilidad, IVI VALENCIA
ClinicalTrials.gov Identifier:
NCT00625950
First received: February 20, 2008
Last updated: January 9, 2009
Last verified: January 2009
  Purpose

Dopamine agonists, such as quinagolide, are able to act on the VEGFR-2 blocking antibodies, diminishing Vascular Endothelial Growth Factor effect on angiogenesis in human endometriotic lesions.


Condition Intervention Phase
Hyperprolactinemia
Endometriosis
Procedure: ENDOMETRIAL BIOPSY
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Effect of Treatment With Agonist Dopaminergics on Endometriosic Lesions.

Resource links provided by NLM:


Further study details as provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:

Primary Outcome Measures:
  • observation of three month treatment with Quinagolida in endometriosis patients [ Time Frame: onset and three months after onset ] [ Designated as safety issue: No ]

Estimated Enrollment: 5
Study Start Date: February 2008
Study Completion Date: May 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: ENDOMETRIAL BIOPSY
    Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
  Eligibility

Ages Eligible for Study:   18 Years to 37 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Hyperprolactinemia
  • Unexplained infertility
  • Endometriosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00625950

Locations
Spain
Instituto Valenciano de Infertilidad
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, IVI VALENCIA
  More Information

No publications provided by Instituto Valenciano de Infertilidad, IVI VALENCIA

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. Antonio Pellicer, Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier: NCT00625950     History of Changes
Other Study ID Numbers: VLC-AP-10208-208-1
Study First Received: February 20, 2008
Last Updated: January 9, 2009
Health Authority: Spain: Ethics Committee

Keywords provided by Instituto Valenciano de Infertilidad, IVI VALENCIA:
Hyperprolactinemia
Endometriosis
laparoscopy
angiogenesis, VEGF

Additional relevant MeSH terms:
Endometriosis
Hyperprolactinemia
Genital Diseases, Female
Hyperpituitarism
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on July 23, 2014